TCT 2022 | FRANCE-TAVI Registry: Small Annuli

The presence of small annuli, defined in this registry as < 23 mm diameter or indexed diameter <12 mm/m2 by CT, continues to be one of the greatest challenges of both surgical and endovascular aortic valve treatments.

TCT 2022

The FRANCE-TAVI Registry looked at 1,195 patients presenting small annuli. 895 (74.9%) received balloon expandable valves (BEV) and 300 self-expanding valves (SEV).

After adjusting with propensity score, due to population mismatch, 696 BEV and 232 SEV patients were matched.

Primary end point was permanent pacemaker implantation moderate to severe PPMI at one year. 

Mean age was 82 and EuroScore was 4.5. Ejection fraction was 60%.

The most frequent approach was femoral (close to 90%), there were no differences in predilution or in valve diameter. 

In hospital complications were low and with no differences, but the need for pacemaker implantation was higher in the SEV group (9.3% vs. 18.3% p=0.003).

Read also: Primary vs Secondary Retrograde Approach in CTO: Differences.

Primary end point resulted in favor of SEV, severe PPMI 8% vs. 3.5% (p=<0.001 and PPMI moderate or severe 38.5% vs. 15.6% p<0.001).

Mean gradient and valve area at one year were also in favor of SEV, 13.8 mmHg, vs 8.5 mmHg p=<0.001 and 1.1 cm2/m2 vs 0.9 cm2/m2.

At 3 years, mortality was higher in PPMI patients, as was the presence of atrial fibrillation. 

Read also: Is the Cause of Mitral Regurgitation Relevant for MitraClip?

The authors have concluded that SEV presented lower PPMI rate and better hemodynamic profile, in addition to PPMI being associated to higher mortality. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Transcatheter Aortic Valve Replacement in Small Aortic Annuli: Results From the FRANCE-TAVI Registry. Walid Ben-Al.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....